Table 2.

Frequencies of APOBEC3G gene polymorphisms (cases vs. controls)

					HIV (+) versus HIV(−)/HBV(−)			HBV(+) versus HIV(−)/HBV(−)			HIV(+)/HBV(+) versus HIV(−)/HBV(−)
Polymorphisms	HIV(+)	HBV(+)	HIV(+)/HBV(+)	HIV(−)/HBV(−)	OR	95 % CI	p-Value	OR	95 % CI	p-Value	OR	95 % CI	p-Value
	(n = 35)	(n = 65)	(n = 85)	(n = 239)
rs6001417
CC, n (%)	10 (28.57)	15 (0.23)	26 (30.59)	64 (0.27)	1.09	0.5–2.4	0.84	0.82	0.43–1.56	0.63	1.2	0.7–2.07	0.57
CG, n (%)	17 (48.57)	40 (0.61)	48 (56.47)	114 (0.48)	1.03	0.51–2.1	1	1.75	1.01–3.07	0.05	1.47	0.89–2.42	0.13
GG, n (%)	8 (22.86)	10 (0.15)	11 (12.94)	61 (0.25)	0.415	0.37–2	0.84	0.415	0.37–2	0.84	0.415	0.207–0.83	0.02
G vs C, n (%)	33 (0.94)	60 (.92)	35 (0.41)	236 (0.99)	0.9	0.55–1.51	0.8	0.82	0.55–1.2	0.32	0.759	0.5–1.06	0.06
HWE	0.74	0.16	0.20	0.38	–	–	–	–	–	–	–	–	–
rs8177832
AA. n (%)	10 (28.57)	15 (0.23)	27 (31.76)	69 (28.87)	0.98	0.45–2.16	1	0.74	0.39–1.4	0.43	1.15	0.67–1.96	0.7
AG. n (%)	18 (0.51)	40 (0.61)	45 (52.94)	111 (0.46)	1.22	0.60–2.48	0.59	1.84	1.05–3.23	0.04	1.34	0.82–2.2	0.26
GG. n (%)	7(0.2)	10 (0.15)	13 (15.30)	59 (0.25)	0.76	0.32–1.84	0.67	0.55	0.26–1.15	0.13	0.53	0.28–1.02	0.07
G vs A. n (%)	32 (0.91)	60 (0.92)	36 (42.35)	229 (0.96)	0.9	0.55–1.51	0.8	0.82	0.55–1.2	0.32	0.77	0.54–1.09	0.15
HWE	0.98	0.16	0.59	0.21	–	–	–	–	–	–	–	–	–
rs35228531
CC. n (%)	18 (0.51)	18 (0.51)	40 (47.05)	84 (35.15)	1.95	0.96–4	0.09	1.15	0.65–2.03	0.66	1.64	0.99–2.71	0.07
CT. n (%)	15 (0.43)	15 (0.43)	38 (44.70)	113 (0.47)	0.84	0.4–1.71	0.17	0.95	0.55–1.65	0.89	0.93	0.57–1.53	0.80
TT. n (%)	2 (0.06)	2 (0.06)	7 (8.25)	42 (0.17)	0.28	0.06–1.23	0.09	0.85	0.40–1.80	0.85	0.4	0.17–0.9	0.04
T vs C. n (%)	19 (0.54)	19 (0.54)	25 (29.88)	197 (0.82)	0.53	0.3–0.93	0.03	0.89	0.6–1.33	0.615	0.61	0.42–0.90	0.01
HWE	0.88	0.98	0.86	0.55	–	–	–	–	–	–	–	–	–

HWE Hardy-Weinberg equilibrium, OR odds ratio, CI confidence interval. Significant p-Values are in bold